Cost-effectiveness of treatments for major depression in primary care practice

Archives of General Psychiatry

Volumn 55, Issue 7, 1998, Pages 645-651

  Lave, Judith R ^a   Frank, Richard G ^b   Schulberg, Herbert C ^c   Kamlet, Mark S ^d  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORTRIPTYLINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; PRIMARY HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031823768     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.7.645     Document Type: Article

References (35)

1. National Committee on Quality Assurance. Health Plan Employer Data and Information Set, Version 3.0. Washington, DC: National Committee on Quality Assurance; 1997.
2. American Managed Behavioral Health Association. PERMS 2.0. Washington, DC: American Managed Behavioral Health Association; 1997, 27261.
3. Foundation for Accountability. Available at: http://www.faact.org.Accessed March 4, 1998.
4. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
5. Clinical Practice Guideline Number 5: Depression in Primary Care 2: Detection and Diagnosis. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-05501.
6. Schulberg HC, Block MR, Madonia MJ, Scott CP, Rodhguez E, Imber SO, Perel J, Lave JR, Houck PR, Coulehman JL. Treating major depression in primary care practice: eight-month clinical outcomes. Arch Gen Psychiatry. 1996;53:913-919.
7. Schulberg HC, Madonia MJ, Block MR, Coulehan JL, Scott CP, Rodriguez E, Black A. Major depression in primary care practice. Psychosomatics. 1995;36: 129-137.
8. Schulberg HC, Block MR, Madonia MJ: Scott CP, Lave JR, Rodriguez E, Coulehan JL. The "usual care" of major depression in primary care practice. Arch Fam Med. 1997;6:334-339.
9. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry.1960; 23:56-62.
10. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53-63.
11. Brown C, Schulberg HC, Madonia MJ. Assessing depression in primary care practice with the Beck Depression Inventory and the Hamilton Rating Scale for depression. Psychol Assess. 1995;7:59-65.
12. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depression disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
13. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1972;31 697-704.
14. Rubin HC, Patterson TL, Atkinson JH, Kaplan RM, Doch WL, McCutchar JA, Chandler JL, Grant I. Tracking effects of depression on life quality in HIV. Paper presented at the Second Conference on Biopsychosocial Aspects of HIV Infections; July 8, 1994; Brighton, England.
15. Kaplan RM. Using general measures of health related quality of life to assess mental health outcomes. In: Miller NE, Magruder KM, eds, Cost-Effectiveness of Psychotherapy: A Guide for Practioners, Researchers, and Policy-Makers. New York, NY: John Wiley & Sons. In press.
16. Fryback DG, Dasbach EJ, Klein R, Klein BEK, Dorn N, Peterson K, Martin PA. The Beaver Dam health outcomes study: initial catalog of health state quality factors. Med Decis Making. 1993;13:89-102.
17. 1995 Redbook. Montvale, NJ: Medical Economics Data, Inc; 1995.
18. Mumford E, Schlesinger HJ, Glass GV, Patrick P, Guerdon T. A new look at evidence about reduced cost of medical utilization following mental health treatment. Am J Psychiatry. 1984;14:1145-1158.
19. Borus JF, Olendzki MC, Kessler L, Burns BJ, Brandt UC, Broverman CA, Henderson PR. The offset effect of mental health treatment on ambulatory medical care utilization and charges. Arch Gen Psychiatry. 1985;42:573-580.
20. State of Arizona, Office of the Auditor General. Performance Audit. Phoenix, Ariz: Dept of Health Services, Division of Behavioral Health Services; December 1996. Report 96-19.
21. Beauregard KP, Cunninghan P, Cornelius L. Access to Health Care: Findings From the Survey of American Indians and Alaska Natives: National Medical Expenditure Survey Findings 9. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1991. AHCPR publication 91-0028.
22. US Bureau of the Census. Census of Population and Housing: 1990. Washington, DC: US Bureau of the Census.
23. Gibbons R, Hedeker D, Elkin I, Watermaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry. 1993;50:739-750.
24. Mullahy J, Manning WG. Statistical issues in cost effectivness analysis: In: Sloan F, ed. Valuing Health Care: Costs, Benefits and Effectivness of Pharmaceuticals and Other Medical Technologies. New York, NY: Cambridge University Press; 1994:149-184.
25. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in costeffectivenss analysis. In:Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. CostEffectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:247-276.
26. Parkerman H, Broadhead W, TSE C. The Duke Severity of Illness Checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol. 1993;46:379-393.
27. Stewart AL, Hays RD, Ware JE. The MOS Short-Form General Health Survey. Med Care. 1988;26:724-735.
28. Laupacis A, Fenny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
29. Meltzer, D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16:33-64.
30. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA. 1995;273:51-58.
31. Von Korff M, Katon W, Bush T, Lin EHB, Simon GE, Saunders K, Ludman E, Walker E, Unutzer J. Treatment costs, cost offset and cost effectiveness of collaborative management of depression. Psychosom Med. 1998;60:143-149.
32. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. JAMA. 1996;275:1897-1902.
33. Grof P. Designing long-term clinical trials in affective disorders. J Affect Disord. 1994;30:243-255.
34. Heckman JJ, Smith JA. Assessing the case for social experiments. J Econ Perspectives. 1995;9:85-110.
35. Lave JR, Schulberg HC. Integrating cost-effectiveness analyses within clinical trials of treatment for major depression in primary care practice. In: Miller NE, Magruder KM, eds. Cost-Effectiveness of Psychotherapy: A Guide for Practitoners, Researchers, and Policy-Makers. New York, NY: John Wiley & Sons. In press.